Alka-Seltzer Plus
This article was originally published in The Tan Sheet
Executive Summary
Withdrawal of PPA-containing cold medicines estimated to cost Bayer [Euro]60 mil. to [Euro]80 mil. ($50.9 mil. to $67.9 mil), company says during recent analysts conference. The Alka-Seltzer Plus brand was heavily impacted by FDA's Nov. 3 letter requesting that manufacturers voluntarily discontinue marketing drugs containing phenylpropanolamine. All six effervescent products in the cough/cold line contain PPA; the five Liqui-Gel products are PPA free. Bayer says it hopes to introduce reformulated effervescent products in early 2001 (1"The Tan Sheet" Nov. 13, p. 4)